Better Buy: Biogen vs. Eli Lilly
Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new therapies: Alzheimer's disease (AD).
However, these two stocks have moved in very different directions over the past three years, with Eli Lilly delivering substantially better returns to its shareholders. Will that continue to be the case? Or will Biogen be the better performer from here on out?
Source Fool.com
Biogen Inc. Stock
€188.45
-3.150%
With 53 Buy predictions and 2 Sell predictions Biogen Inc. is one of the favorites of our community.
As a result the target price of 289 € shows a very positive potential of 53.36% compared to the current price of 188.45 € for Biogen Inc..
